Lonza and Asimov Partner on Lentiviral Vector GMP Manufacturing
- Lonza and Asimov combine Asimov's LV Edge stable cell line technology with Lonza's process development, scale-up, analytics, and GMP manufacturing capabilities for lentiviral vectors.
- The collaboration addresses scalability and consistency limitations of current multi-plasmid transient transfection methods, targeting in vivo and ex vivo gene therapy applications.
- Partnership spans transgene optimization, cell line development, process development, advanced analytics, scale-up, GMP manufacturing, and CMC readiness.
Operational Impact
Lonza's expanded lentiviral vector GMP capabilities and feasibility-first framework with Asimov create a defined pathway for gene therapy developers to transition from early design through clinical and commercial manufacturing, potentially increasing demand for Lonza's specialized modalities capacity.
Source: PharmaSource RSS
Curia Invests $28M in Sterile API Expansion at Valladolid Site
- Curia is investing $28 million to expand sterile API manufacturing for steroid and non-steroid products at its Valladolid, Spain facility, with completion targeted for Q4 2028.
- The expansion adds closed-system barrier isolators for aseptic handling and enables variable batch-size manufacturing from grams to metric tons for injectable suspensions and complex sterile formulations.
- This follows Curia's $4 million API aseptic suite upgrade in Valladolid (May 2026) and concurrent expansions in New Mexico and Glasgow, signaling multi-geography capacity growth.
Operational Impact
Curia's Valladolid sterile API expansion adds European capacity for variable-batch injectable manufacturing, reducing lead times and supply risk for sponsors developing complex sterile formulations.
Source: Contract Pharma Breaking News RSS
MedPharm Lands Fifth Commercial Manufacturing Deal in 20 Months
- MedPharm signed a commercial manufacturing agreement with a global pharma company for a branded specialty topical product, marking its fifth deal in 20 months.
- The Durham, North Carolina site will handle site transfer and commercial production, generating technology transfer revenue in 2026–2027 and manufacturing revenue starting 2027.
Operational Impact
MedPharm's Durham site adds another commercial topical manufacturing program, demonstrating sustained demand for its specialty formulation capabilities and expanding its commercial revenue base into 2027.
Source: Contract Pharma Breaking News RSS